Charles Bennett to Immunologic Factors
This is a "connection" page, showing publications Charles Bennett has written about Immunologic Factors.
Connection Strength
1.634
-
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR). Cancer Med. 2017 Jul; 6(7):1541-1551.
Score: 0.529
-
Pharmacovigilance and PML in the oncology setting. Cleve Clin J Med. 2011 Nov; 78 Suppl 2:S13-7.
Score: 0.358
-
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009 Aug; 10(8):816-24.
Score: 0.306
-
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006 Dec 06; 296(21):2558-60.
Score: 0.255
-
Cost-effectiveness considerations in the treatment of essential thrombocythemia. Semin Oncol. 2002 Jun; 29(3 Suppl 10):28-32.
Score: 0.186